drugset / Trial / NCT01316237
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
Summary
A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects with Chronic Hepatitis C Virus Infection.
Timeline
- Start
- 2011-01
- Primary completion
- 2011-10
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GS-6620 | Small molecule | 50 mg | Oral |
| Subject | GS-6620 | Small molecule | 100 mg | Oral |
| Subject | GS-6620 | Small molecule | 300 mg | Oral |
| Subject | GS-6620 | Small molecule | 450 mg | Oral |
| Subject | GS-6620 | Small molecule | 900 mg | Oral |